In an interview with Christine Moutier, MD, psychiatrist and chief medical officer of the American Foundation for Suicide Prevention, she speaks about how the current COVID-19 pandemic presents opportunities to improve suicide prevention efforts on multiple levels.
Natalia Skritskaya, PhD, Clinical Psychologist and Research Scientist at the Center for Complicated Grief, Columbia School of Social Work in New York gives her take on the subject of complicated grief.
Adolescents’ psychological challenges are increasingly entangled with their experiences online and virtual interactions with their peers on social media. We look at what this means during the COVID-19 pandemic.
COVID-19 has caused disruptions all across the world. In this piece, we take a look at what working during the pandemic has been like for psychiatric residents, as well as opportunities that the current situation has offered for learning.
This review examines the nerurobiological mechanisms, risk factors, conceptual models, clinical challenges and management for individuals with antidepressant associated hypomania. Greater clarity is required regarding underlying biological mechanisms and the best treatment approaches to assist with clinical decision-making.
Since publication of the last full practice guideline and guideline watch on schizophrenia, there have been a multitude of studies on new pharmacological and nonpharmacological treatments for schizophrenia.
This systematic review further explores whether alterations of the HPA axis that are commonly found in patients with major depressive disorder are due to early life stress or whether the alterations are caused by the MDD itself.
The dual pandemics of COVID-19 and racism as public health crises have led to an awakening among non-Black Americans as to how rampant racism is in the field of psychiatry and other mental health disciplines.
Although brain stimulation techniques are not considered first-line treatments, these are often used in treatment-resistant depression, with electroconvulsive therapy representing the established best therapeutic option for treatment-resistant depression.
Personalized medicine “promises to move beyond data regarding the average effectiveness of treatments to identify the best treatment for any individual.” However, personalized medicine for depression necessitates “identifying characteristics of individuals that reliably predict differences in benefits and/or adverse effects of alternative depression treatments, including both biological and psychosocial treatments.”
As an increasing number of patients are seeking professional treatment for attachment disorders, clinicians need to stay up to date on the latest developments to mitigate the far-reaching effects of these conditions.
A substantial body of research points to a multifaceted link between depression and cardiovascular disease, with rates of depression being 3 times higher in patients with coronary artery disease compared to the general population